Where does Rebound Therapeutics Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rebound Therapeutics Corporation ranks #11,784 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rebound Therapeutics Corporation hold?

Rebound Therapeutics Corporation holds 26 US utility patents granted between 2018 and 2025, spanning 5 technology areas.

What is Rebound Therapeutics Corporation's Innovation Score?

Rebound Therapeutics Corporation has an Innovation Score of 32.1 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Rebound Therapeutics Corporation focus on?

Rebound Therapeutics Corporation's top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 26 patents, ranking #709 of 7,127 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Rebound Therapeutics Corporation's patent grant rate increasing or decreasing?

Rebound Therapeutics Corporation's recent grant velocity is +157% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Rebound Therapeutics Corporation's patents?

Rebound Therapeutics Corporation's patents average 11.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rebound Therapeutics Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Rebound Therapeutics Corporation

USPTO PatentsView assignee record - 26 granted patents across 5 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Rebound ranks #11,784 of 49,997 tracked US assignees by granted-patent volume, with 26 patents across 5 technology areas.

#11,784
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.1/100): 11.2
avg claims per patent: +157%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11784 · US Corporation #11,784 · 26 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 26 grants
UPPER-Q #11,784/49,997
PHOTO-FINISH Rampart Communications
CPC-NARROW A61B · 5 areas
INNOV-THIN 32.1/100
CLAIMS-PAR 11.2 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +157% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Rampart Communications, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Rebound’s 32.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.4 pts (36%) Velocity 6.1 pts (19%) Breadth 7.9 pts (25%) Claim depth 6.7 pts (21%)

Qualcomm Incorporated · highest

85
Ariosa Diagnostics · near

32
Encore Packaging · near

32
Kleverness Incorpora… · near

32
Rebound Therapeutics · this assignee

32
Athalonz · near

32
3D Lighting… · lowest

7

What this shows Rebound's Innovation Score is 32.1/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Rebound?

Each dot is one of Rebound’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rebound’s own 11.2 claims/patent is at or below the 15.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Rebound vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Rebound's grants concentrate

Rebound Therapeutics Corporation is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2019 (5 grants) versus a trough of 2 in 2018. By volume, Rebound sits between Revmedica, Inc. and Shanghai Institute OF Organic Chemistry, Chinese Academy OF Sciences.

Rebound's three-year grant acceleration

Rebound Therapeutics Corporation shows 11 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Revmedica

26
Roddie

26
Rosenberger

26
Rampart Communica…

26
Regal Beloit Aust…

26
Research Products

26
Semicon Light

26
Shanghai Institut…

26
Rebound Therapeut… ◀

26

What this shows Rebound holds 26 patents at rank #11,789, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rebound

By rank, the assignees closest to #11,789 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Rebound's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Rebound, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Rebound ranks #709 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (32 here).

Ariosa Diagnostics, Inc. 32 Encore Packaging LLC 32 Kleverness Incorporated 32 Athalonz, LLC 32

Rebound's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Rebound Therapeutics Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	2	7.7%
2019	5	19.2%
2020	4	15.4%
2021	3	11.5%
2022	2	7.7%
2023	5	19.2%
2024	4	15.4%
2025partial year	1	3.8%

Which technologies does Rebound Therapeutics Corporation patent most?

A61B - DIAGNOSIS; SURGERY; Identification 26

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

G03B - Apparatus OR Arrangements FOR Taking Photographs OR FOR Projecting OR Viewing THEM; Apparatus OR Arrangements Employing Analogous Techniques Using Waves Other Than Optical WAVES; Accessories Therefor 1

H04N - Pictorial Communication, e.g. Television 1

G06T - Image Data Processing OR Generation, IN General 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Rebound Therapeutics Corporation's patent record in context - here's where to go next.

Rebound Therapeutics Corporation's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #11,784 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Rebound Therapeutics Corporation against Revmedica, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.